Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 43.1
(2.13%)
HKD 43.1
(2.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.25 Billion CNY | -11.28% |
| 2022 | 2.54 Billion CNY | -0.08% |
| 2021 | 2.54 Billion CNY | 118.94% |
| 2020 | 1.16 Billion CNY | 63.06% |
| 2019 | 713.23 Million CNY | 5.7% |
| 2018 | 674.77 Million CNY | 39.95% |
| 2017 | 482.16 Million CNY | -21.2% |
| 2016 | 611.9 Million CNY | 82.94% |
| 2015 | 334.48 Million CNY | 22.52% |
| 2014 | 273 Million CNY | 20.22% |
| 2013 | 227.08 Million CNY | 3.25% |
| 2012 | 219.93 Million CNY | -14.8% |
| 2011 | 258.14 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.23 Billion CNY | -1.01% |
| 2024 Q2 | 2.4 Billion CNY | 7.66% |
| 2024 Q3 | 2.06 Billion CNY | -14.18% |
| 2023 Q4 | 2.25 Billion CNY | -1.54% |
| 2023 Q2 | 2.4 Billion CNY | 10.48% |
| 2023 FY | 2.25 Billion CNY | -11.28% |
| 2023 Q3 | 2.29 Billion CNY | -4.68% |
| 2023 Q1 | 2.17 Billion CNY | -14.44% |
| 2022 Q3 | 3 Billion CNY | -7.55% |
| 2022 FY | 2.54 Billion CNY | -0.08% |
| 2022 Q4 | 2.54 Billion CNY | -15.26% |
| 2022 Q2 | 3.24 Billion CNY | 12.95% |
| 2022 Q1 | 2.87 Billion CNY | 12.93% |
| 2021 Q1 | 1.12 Billion CNY | -2.97% |
| 2021 Q2 | 1.4 Billion CNY | 24.92% |
| 2021 Q4 | 2.54 Billion CNY | 37.55% |
| 2021 FY | 2.54 Billion CNY | 118.94% |
| 2021 Q3 | 1.85 Billion CNY | 31.31% |
| 2020 Q3 | 1.09 Billion CNY | 44.72% |
| 2020 Q1 | 682.52 Million CNY | -4.31% |
| 2020 Q4 | 1.16 Billion CNY | 6.21% |
| 2020 Q2 | 756.6 Million CNY | 10.85% |
| 2020 FY | 1.16 Billion CNY | 63.06% |
| 2019 FY | 713.23 Million CNY | 5.7% |
| 2019 Q2 | 575.21 Million CNY | -4.43% |
| 2019 Q1 | 601.85 Million CNY | -10.81% |
| 2019 Q3 | 713.12 Million CNY | 23.97% |
| 2019 Q4 | 713.23 Million CNY | 0.02% |
| 2018 Q2 | 518.4 Million CNY | 5.29% |
| 2018 FY | 674.77 Million CNY | 39.95% |
| 2018 Q4 | 674.77 Million CNY | 25.64% |
| 2018 Q3 | 537.05 Million CNY | 3.6% |
| 2018 Q1 | 492.36 Million CNY | 2.11% |
| 2017 Q4 | 482.16 Million CNY | -0.17% |
| 2017 Q1 | 557.02 Million CNY | -8.97% |
| 2017 Q2 | 507.58 Million CNY | -8.88% |
| 2017 Q3 | 483 Million CNY | -4.84% |
| 2017 FY | 482.16 Million CNY | -21.2% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q3 | 439.66 Million CNY | -4.78% |
| 2016 Q4 | 611.9 Million CNY | 39.17% |
| 2016 Q2 | 461.76 Million CNY | 0.0% |
| 2016 FY | 611.9 Million CNY | 82.94% |
| 2015 FY | 334.48 Million CNY | 22.52% |
| 2015 Q4 | 334.48 Million CNY | 0.0% |
| 2014 FY | 273 Million CNY | 20.22% |
| 2013 FY | 227.08 Million CNY | 3.25% |
| 2012 FY | 219.93 Million CNY | -14.8% |
| 2011 FY | 258.14 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -1377.038% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 68.02% |